Outlook Therapeutics (OTLK) Misses Q3 EPS by 44c

Outlook Therapeutics (NASDAQ: OTLK) reported Q3 EPS of ($0.44). Revenue for the quarter came in at $1.51 million.

For earnings history and earnings-related data on Outlook Therapeutics (OTLK) click here.

You May Also Be Interested In

• Intel (INTC) PT Lowered to $92 at Mizuho
• Ambarella (AMBA) Tops Q2 EPS by 1c; offers guidance
• Oxford Industries (OXM) Tops Q2 EPS by 4c; offers guidance